References
- 1.Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S. Nampt/ PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007;6(5):363-75; DOI:10.1016/j. cmet.2007.09.003.10.1016/j.cmet.2007.09.003
- 2. Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr. 2008;28:115-30; DOI:10.1146/annurev. nutr.28.061807.155443.10.1146/annurev.nutr.28.061807.155443
- 3. Houtkooper RH, Canto C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev. 2010; 31(2):194-223; DOI:10.1210/er.2009-0026.10.1210/er.2009-0026
- 4. Borradaile NM, Pickering JG. NAD(+), sirtuins, and cardiovascular disease. Curr Pharm Des. 2009;15(1):110-7.10.2174/138161209787185742
- 5. Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA, Sartorelli V. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell. 2008;14(5):661-73; DOI:10.1016/j.devcel.2008.02.004.10.1016/j.devcel.2008.02.004
- 6. Hsu CP, Oka S, Shao D, Hariharan N, Sadoshima J. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ Res. 2009; 105(5):481-91; DOI:10.1161/ CIRCRESAHA.109.203703.10.1161/CIRCRESAHA.109.203703
- 7. Pillai JB, Isbatan A, Imai S, Gupta MP. Poly(ADP-ribose) polymerase- -1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J Biol Chem. 2005;280(52):43121-30; DOI:10.1074/jbc.M506162200.
- 8. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49):50754-63; DOI:10.1074/ jbc.M408388200.
- 9. Rongvaux A, Galli M, Denanglaire S, Van Gool F, Dreze PL, Szpirer C, Bureau F, Andris F, Leo O. Nicotinamide phosphoribosyl transferase/ pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol. 2008;181(7):4685-95.
- 10. Song EK, Lee YR, Yu HN, Kim UH, Rah SY, Park KH, Shim IK, Lee SJ, Park YM, Chung WG, Kim JS, Han MK. Extracellular NAD is a regulator for FcgammaR-mediated phagocytosis in murine macrophages. Biochem Biophys Res Commun. 2008;367(1):156-61; DOI:10.1016/j bbrc.2007.12.131.
- 11. Chen H, Wang S, Zhang H, Nice EC, Huang C. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities. Expert Rev Anticancer Ther. 2016;16(8):827-38; DOI:10.1080/147371 40.2016.1190649.
- 12. Chiarugi A, Dolle C, Felici R, Ziegler M. The NAD metabolome--a key determinant of cancer cell biology. Nat Rev Cancer. 2012;12(11):741-52; DOI:10.1038/nrc3340.10.1038/nrc3340
- 13. Shackelford RE, Mayhall K, Maxwell NM, Kandil E, Coppola D. Nicotinamide phosphoribosyltransferase in malignancy: a review. Genes Cancer. 2013;4(11-12):447-56; DOI:10.1177/1947601913507576.10.1177/1947601913507576
- 14. Nergiz Avcioglu S, Altinkaya SO, Kucuk M, Yuksel H, Omurlu IK, Yanik S. Visfatin concentrations in patients with endometrial cancer. Gynecol Endocrinol. 2015;31(3):202-7; DOI:10.3109/09513590.2014.975687.10.3109/09513590.2014.975687
- 15. Zhao Y, Hu Q, Cheng F, Su N, Wang A, Zou Y, Hu H, Chen X, Zhou HM, Huang X, Yang K, Zhu Q, Wang X, Yi J, Zhu L, Qian X, Chen L, Tang Y, Loscalzo J, and Yang Y, SoNar, a Highly Responsive NAD+/NADH Sensor, Allows High-Throughput Metabolic Screening of Anti-tumor Agents. Cell Metab. 2015;21(5):777-89; DOI:10.1016/j.cmet.2015.04.009.10.1016/j.cmet.2015.04.009
- 16. Bi TQ, Che XM. Nampt/PBEF/visfatin and cancer. Cancer Biol Ther. 2010;10(2):119-25; DOI:10.4161/cbt.10.2.12581.10.4161/cbt.10.2.12581
- 17. Shackelford RE, Bui MM, Coppola D, Hakam A. Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int J Clin Exp Pathol. 2010;3(5):522-7.
- 18. Buldak RJ, Buldak L, Polaniak R, Kukla M, Birkner E, Kubina R, Kabala- Dzik A, Dulawa-Buldak A, Zwirska-Korczala K. Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study. Oncol Rep. 2013;29(2):771-8; DOI:10.3892/or.2012.2175.
- 19. Olesen UH, Petersen JG, Garten A, Kiess W, Yoshino J, Imai S, Christensen MK, Fristrup P, Thougaard AV, Bjorkling F, Jensen PB, Nielsen SJ, Sehested M. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. BMC Cancer. 2010;10:677; DOI:10.1186/1471-2407-10-677.
- 20. Guo J, Lam LT, Longenecker KL, Bui MH, Idler KB, Glaser KB, Wilsbacher JL, Tse C, Pappano WN, Huang TH. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD(+) biosynthesis pathway and NAMPT mutation. Biochem Biophys Res Commun. 2017;491(3):681-686; DOI:10.1016/j.bbrc.2017.07.143.10.1016/j.bbrc.2017.07.143
- 21. Carbone F, Liberale L, Bonaventura A, Vecchie A, Casula M, Cea M, Monacelli F, Caffa I, Bruzzone S, Montecucco F, Nencioni A. Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin. Compr Physiol. 2017;7(2):603-621; DOI:10.1002/cphy.c160029.10.1002/cphy.c160029
- 22. Garten A, Schuster S, Penke M, Gorski T, de Giorgis T, Kiess W. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol. 2015;11(9):535-46; DOI:10.1038/nrendo.2015.117.10.1038/nrendo.2015.117
- 23. Gholinejad Z, Kheiripour N, Nourbakhsh M, Ilbeigi D, Behroozfar K, Hesari Z, Golestani A, Shabani M, Einollahi N. Extracellular NAMPT/ Visfatin induces proliferation through ERK1/2 and AKT and inhibits apoptosis in breast cancer cells. Peptides. 2017;92:9-15; DOI:10.1016/j. peptides.2017.04.007.10.1016/j.peptides.2017.04.007
- 24. Behrouzfar K, Alaee M, Nourbakhsh M, Gholinejad Z, Golestani A. Extracellular NAMPT/visfatin causes p53 deacetylation via NAD production and SIRT1 activation in breast cancer cells. Cell Biochem Funct.2017;35(6):327-333; DOI:10.1002/cbf.3279.10.1002/cbf.3279
- 25. Patel ST, Mistry T, Brown JE, Digby JE, Adya R, Desai KM, Randeva HS. A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides. 2010;31(1):51-7, DOI:10.1016/j. peptides.2009.10.001.10.1016/j.peptides.2009.10.001
- 26. Ninomiya S, Shimizu M, Imai K, Takai K, Shiraki M, Hara T, Tsurumi H, Ishizaki S, Moriwaki H. Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells. Cancer Prev Res (Phila). 2011;4(12):2092-100; DOI:10.1158/1940-6207.CAPR-11-0340.10.1158/1940-6207.CAPR-11-0340
- 27. Mohammadi M, Zarghami N, Hedayati M, Ghaemmaghami S, Yamchi RM, Mohaddes M. Visfatin effects on telomerase gene expression in AGS gastric cancer cell line. Indian J Cancer. 2015;52(1):32-5; DOI:10.4103/0019-509X.175567.10.4103/0019-509X.175567
- 28. Wang G, Tian W, Liu Y, Ju Y, Shen Y, Zhao S, Zhang B, Li Y. Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases. Basic Clin Pharmacol Toxicol. 2016;119(6):548- 554; DOI:10.1111/bcpt.12623.10.1111/bcpt.12623
- 29. Reverchon M, Rame C, Bunel A, Chen W, Froment P, Dupont J. VISFATIN (NAMPT) Improves In Vitro IGF1-Induced Steroidogenesis and IGF1 Receptor Signaling Through SIRT1 in Bovine Granulosa Cells. Biol Reprod. 2016;94(3):54; DOI:10.1095/biolreprod.115.134650.10.1095/biolreprod.115.134650
- 30. Diot M, Reverchon M, Rame C, Baumard Y, Dupont J. Expression and effect of NAMPT (visfatin) on progesterone secretion in hen granulosa cells. Reproduction. 2015;150(1):53-63; DOI:10.1530/REP-15-0021.10.1530/REP-15-0021
- 31. Diot M, Reverchon M, Rame C, Froment P, Brillard JP, Briere S, Leveque G, Guillaume D, Dupont J. Expression of adiponectin, chemerin and visfatin in plasma and different tissues during a laying season in turkeys. Reprod Biol Endocrinol. 2015;13:81; DOI:10.1186/s12958-015-0081-5.10.1186/s12958-015-0081-5
- 32. Ocon-Grove OM, Krzysik-Walker SM, Maddineni SR, Hendricks GL 3rd, Ramachandran R. NAMPT (visfatin) in the chicken testis: influence of sexual maturation on cellular localization, plasma levels and gene and protein expression. Reproduction. 2010;139(1):217-26; DOI:10.1530/REP-08-0377.10.1530/REP-08-0377
- 33. Celichowski P, Jopek K, Milecka P, Szyszka M, Tyczewska M, Malendowicz LK, Ruciński M. Nicotinamide phosphoribosyltransferase (Nampt)and the hypothalamic-pituitary-adrenal axis of the rat. Mol Med Rep.2018;17(4):6163-6173; DOI:10.3892/mmr.2018.8569.10.3892/mmr.2018.8569
- 34. Trejter M, Hochol A, Tyczewska M, Ziolkowska A, Jopek K, Szyszka M,MalendowiczLK, Rucinski M. Visinin-like peptide 1 in adrenal gland of the rat. Gene expression and its hormonal control. Peptides. 2015;63:22-9; DOI:10.1016/j.peptides.2014.10.017.10.1016/j.peptides.2014.10.017
- 35. Ziolkowska A, Rucinski M, Tyczewska M, Malendowicz LK. Orexin B inhibits proliferation and stimulates specialized function of cultured rat calvarial osteoblast-like cells. Int J Mol Med. 2008;22(6):749-55.
- 36. Rucinski M, Ziolkowska A, Szyszka M, Hochol A, Malendowicz LK. Evidence suggesting that ghrelin O-acyl transferase inhibitor acts at the hypothalamus to inhibit hypothalamo-pituitary-adrenocortical axis function in the rat. Peptides. 2012; 35(2):149-59; DOI:10.1016/j. peptides.2012.04.007.10.1016/j.peptides.2012.04.007
- 37. Fazeli MS, Dashti H, Akbarzadeh S, Assadi M, Aminian A, Keramati MR, Nabipour I. Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine. 2013;62(1):81-5; DOI:10.1016/j. cyto.2013.02.012.10.1016/j.cyto.2013.02.012
- 38. Nakajima TE, Yamada Y, Hamano T, Furuta K, Gotoda T, Katai H, Kato K, Hamaguchi T, Shimada Y. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol. 2009;44(7):685-90; DOI:10.1007/s00535-009-0063-5.10.1007/s00535-009-0063-5
- 39. Yu-Duan T, Chao-Ping W, Chih-Yu C, Li-Wen L, Tsun-Mei L, Chia-Chang H, Fu-Mei C, Hsien-Chang L, Hsia-Fen H, Yau-Jiunn L, Jer-Yiing H. Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in male oral squamous cell carcinoma patients. Med Oral Patol Oral Cir Bucal. 2013;18(2):e180-6.
- 40. Talavera-Urquijo E, Rodriguez-Navarro S, Beisani M, Salcedo-Allende MT, Chakkur A, Arus-Aviles M, Cremades M, Augustin S, Martell M, Balibrea JM. Morphofunctional Changes After Sleeve Gastrectomy and Very Low Calorie Diet in an Animal Model of Non-Alcoholic Fatty Liver Disease Obes Surg. 2018;28(1):142-151; DOI:10.1007/s11695-017-2805-4.10.1007/s11695-017-2805-4
- 41. Reddy PS, Umesh S, Thota B, Tandon A, Pandey P, Hegde AS, Balasubramaniam A, Chandramouli BA, Santosh V, Rao MR, Kondaiah P, Somasundaram K. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/gliobastoma serum marker with prognostic value. Cancer Biol Ther. 2008;7(5):663-8.
- 42. Soncini D, Caffa I, Zoppoli G, Cea M, Cagnetta A, Passalacqua M, Mastracci L, Boero S, Montecucco F, Sociali G, Lasiglie D, Damonte P, Grozio A, Mannino E, Poggi A, D’Agostino VG, Monacelli F, Provenzani A, Odetti P, Ballestrero A, Bruzzone S, Nencioni A. Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. J Biol Chem. 2014;289(49):34189-204; DOI:10.1074/jbc.M114.594721.
- 43. Tian W, Zhu Y, Wang Y, Teng F, Zhang H, Liu G, Ma X, Sun D, Rohan T, Xue F. Visfatin, a potential biomarker and prognostic factor for endometrial cancer. Gynecol Oncol. 2013;129(3):505-12; DOI:10.1016/j. ygyno.2013.02.022.10.1016/j.ygyno.2013.02.022
- 44. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003;63(21):7436-42.
- 45. Montecucco F, Cea M, Bauer I, Soncini D, Caffa I, Lasiglie D, Nahimana A, Uccelli A, Bruzzone S, Nencioni A. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Curr Drug Targets. 2013;14(6):637-43.10.2174/1389450111314060003
- 46. Ramachandran J, Suyama AT. Inhibition of replication of normal adrenocortical cells in culture by adrenocorticotropin. Proc Natl Acad Sci U S A. 1975;72(1):113-7.
- 47. Rybak SM, Ramachandran J. Primary culture of normal rat adrenocortical cells. I. Culture conditions for optimal growth and function. In Vitro.1981;17(7):599-604.
- 48. Parmar J, Key RE, Rainey WE. Development of an adrenocorticotropin- responsive human adrenocortical carcinoma cell line. J Clin Endocrinol Metab. 2008;93(11):4542-6; DOI:10.1210/jc.2008-0903.10.1210/jc.2008-0903
- 49. Rainey WE, Saner K, Schimmer BP. Adrenocortical cell lines. Mol Cell Endocrinol. 2004;228(1-2):23-38; DOI:10.1016/j.mce.2003.12.020.10.1016/j.mce.2003.12.020
- 50. Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012;120(17):3519-29; DOI:10.1182/blood-2012-03-416776.10.1182/blood-2012-03-416776